Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2010.359 | A Phase II Study of Transarterial Chemoembolization and Axitinib for the Treatment of Unresectable Hepatocellular Carcinoma | Prof. CHAN Stephen Lam |
| 2013.474 | A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Dr. CHAN Stephen Lam |
| 2014.262 | A Phase 3, Multicenter, Open-label, Randomized Study of nab®-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma | Dr. CHAN Stephen Lam |
| 2011.524 | A study on the ambulatory management of febrile neutropenia in patients with cancer undergoing cytotoxic chemotherapy | Dr. Chan Stephen Lam |
| 2013.001 | A Phase II, open label, single arm, multicenter study of INC280 administered orally in adult patients with advanced hepatocellular carcinoma | Prof. CHAN Stephen Lam |
| 2013.338 | A phase II trial of PEG-BCT-100 as the second-line therapy following sorafenib in patients with advanced hepatocellular carcinoma | Dr. CHAN Stephen Lam |
| 2008.479 | A Randomized Phase I/II, Multi-Center, Open-Label Trial of PR104 and Sorafenib in Patients with Advanced Hepatocellular Carcinoma | Dr. Chan Stephen Lam |
| 2019.694 | A phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to checkpoint inhibitors |
Dr. CHAN Stephen Lam 陳林 |
| 2020.568 | FOENIX-CCA3: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements |
Dr. CHAN Stephen Lam 陳林 |
| 2019.431 | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2020.625 | A PHASE II, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, ADVANCED BILIARY TRACT CANCER |
Dr. CHAN Stephen Lam 陳林 醫生 |
| 2019.259 | Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.458 | A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林 |
| 2019.636 | Targeting and monitoring MDSCs to improve outcomes of radiofrequency ablation in hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.416 | A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1) | Dr. CHAN Stephen Lam |
| 2019.555 | A Phase Ia/Ib, Open-Label, Dose-Escalation and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors |
Dr. CHAN Stephen Lam 陳林 |
| 2019.651 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2) |
Dr. CHAN Stephen Lam 陳林 |
| 2019.454 | A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib (Rivoceranib) Mesylate Versus Sorafenib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy |
Dr. CHAN Stephen Lam 陳林 |
| 2019.474 | A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION |
Prof. CHAN Stephen Lam 陳林 醫生 |
| 2019.387 | A Multicenter, Open-label, Phase I/II Dose Escalation and Expansion Clinical Study to Assess the Safety and Efficacy of MGD013 Monotherapy and in Combination with Brivanib Alaninate (ZL-2301) in Patients with Advanced Liver Cancer | Dr. CHAN Stephen Lam |
| 2019.096 | A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.219 | Study on the clinical role of the Albumin-Bilirubin-index (ALBI) in patients treated with lenvatinib or atezolizumab/bevacizumab for hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2017.653 | A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2017.465 | A clinical trial of pembrolizumab in patients with hepatitis B virus-related hepatocellular carcinoma, with parallel study on baseline and serial change in the immune environment |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2016.730 | A study on thromboembolism in pancreatic cancer patients |
Dr. CHAN Stephen Lam 陳林 |
| 2015.361 | Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib |
Dr. CHAN Stephen Lam 陳林 |
| 2016.172 | A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2017.661 | PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2017.049 | A phase Ib study of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2015.581 | A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Subjects with Advanced Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2014.404 | A Randomized Phase 2 Study of LY2157299 versus LY2157299 – Sorafenib Combination versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma | Prof. CHAN Stephen Lam |
| 2016.393 | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林 |
| 2015.072 | A Phase 3, Randomized, Double-blind,Placebo-controlled Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase | Dr. CHAN Stephen Lam |
| 2014.526 | A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to gemcitabine in combination with placebo, followed as second line treatment by masitinib in combination with Folfiri 3 versus placebo in combination with Folfiri 3 in the treatment of patients with non resectable locally advanced or metastatic pancreatic cancer | Prof. CHAN Stephen Lam |
| 2016.016 | A phase III, Open-label, Randomized Study of the Combination Therapy with NC-6004 and Gemcitabine versus Gemcitabine Alone in Patients with Locally Advanced or Metastatic Pancreatic Cancer |
Dr. CHAN Stephen Lam 陳林 |
| 2014.535 | A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression | Prof. CHAN Stephen Lam |
| 2016.262 | A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2012.404 | A study to evaluate the impact of liver stiffness on treatment outcome of hepatocellular carcinoma | Dr. CHAN Stephen Lam |
| 2013.019 | Determination of association between serum folate level and toxicity of capecitabine in patients with colorectal cancers: A prospective cohort study | Dr. CHAN Stephen Lam |
| 2011.369 | Validation of prognostic markers in advanced hepatocellular carcinoma and identification of potential serological prognostic markers | Dr. CHAN Stephen Lam |
| 2013.020 | Development of staging system based on circulating inflammatory marker for HCC | Dr. Chan Stephen Lam |
| 2011.332 | A Phase 1b, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of EZN-2968, a Hypoxia-Inducible Factor-1 alpha (HIF-1 alpha) mRNA Antagonist, Administered as a Weekly 2-Hour Intravenous Infusion (for 3 Weeks Per 4-Week Cycle) in Adul | Dr. CHAN Stephen Lam |
| 2008.463 | The use of serum hepatitis B viral DNA in prognosticiation of liver cancers undergoing non-surgical therapy | Dr. Chan Stephen Lam |
| 2011.170 | Psychiatric morbidity in Chinese patients with hepatocellular carcinoma | Dr. CHAN Stephen Lam |
| 2024.239 | A PHASE I STUDY OF ERY974 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA | Prof. CHAN Stephen Lam |
| 2024.710 | DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer | Prof. CHAN Stephen Lam |
| 2024.646 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination with Atezolizumab plus Bevacizumab Compared with Placebo plus Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated with Systemic Therapy | Prof. CHAN Stephen Lam |
| 2024.724 | An Open-Label Phase 1/2 Study of WGI-0301 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma as Second Line Therapy |
Prof. CHAN Stephen Lam 陳林 |
| 2024.379 | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements | Prof. CHAN Stephen Lam |
| 2025.184 | A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01) | Prof. CHAN Stephen Lam |
Page 196 of 262.